search
Back to results

Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas (PRISM-UDR)

Primary Purpose

Pneumonia

Status
Terminated
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Murepavadin
One anti-pseudomonal antibiotic
Sponsored by
Polyphor Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pneumonia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

  • Subject has received mechanical ventilation for at least 48h at the time of the randomisation OR at least 2 of the following signs or symptoms presenting within 24 hours prior to randomization: New onset of cough or worsening of baseline cough and/or dyspnea, tachypnea and/or hypoxemia and/or new onset of sputum or suctioned respiratory secretion characterized by purulent appearance indicative of bacterial infection or a worsening in character of purulent appearance
  • Acute Physiology and Chronic Health Evaluation (APACHE) of 8 to 25, inclusive, within 24h prior to randomization
  • Presence of new or progressive infiltrate on chest X-ray
  • Presence of clinical criteria consistent with Pneumonia
  • Strong clinical suspicion of pneumonia due to P. aeruginosa

Key Exclusion Criteria:

  • Known or suspected community-acquired bacterial pneumonia or viral, fungal, or parasitic pneumonia
  • known hypersensitivity to any component of ertapenem, meropenem or to other drugs in the same class or demonstrated anaphylactic reactions to beta-lactams or a history of allergic reactions to any of the penicillins, cephalosporins, or β-lactamase inhibitors
  • Severe liver or renal impairment
  • Expected survival < 72 hours
  • Evidence from an available surveillance culture of co infection with ertapenem , meropenem or piperacillin tazobactam resistant Gram negative pathogen(s)
  • Women who are pregnant or nursing

Sites / Locations

  • Research site
  • Research Site
  • Research site
  • Research site
  • Research site
  • Research site
  • Research site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Murepavadin

Anti-pseudomonal antibiotic

Arm Description

Murepavadin + ertapenem

One anti-pseudomonal-β-lactam-based antibiotic (either meropenem or piperacillin-tazobactam)

Outcomes

Primary Outcome Measures

All cause mortality rates

Secondary Outcome Measures

Full Information

First Posted
June 27, 2018
Last Updated
August 23, 2019
Sponsor
Polyphor Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT03582007
Brief Title
Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas
Acronym
PRISM-UDR
Official Title
A Multicenter, Open Label, Sponsor Blinded, Randomized, Active Controlled, Parallel Group, Pivotal Study to Evaluate the Efficacy, Safety, and Tolerability of Murepavadin Given With Ertapenem Versus an Anti-pseudomonal-β-lactam-based Antibiotic in Adult Subjects With Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas Aeruginosa
Study Type
Interventional

2. Study Status

Record Verification Date
May 2019
Overall Recruitment Status
Terminated
Why Stopped
Safety data review
Study Start Date
October 22, 2018 (Actual)
Primary Completion Date
July 17, 2019 (Actual)
Study Completion Date
July 17, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Polyphor Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a phase 3, multicenter, open-label, sponsor blinded, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous murepavadin given with ertapenem versus an anti-pseudomonal β-lactam based antibiotic in the treatment of nosocomial pneumonia in adult subjects

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pneumonia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
Sponsor blinded
Allocation
Randomized
Enrollment
2 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Murepavadin
Arm Type
Experimental
Arm Description
Murepavadin + ertapenem
Arm Title
Anti-pseudomonal antibiotic
Arm Type
Active Comparator
Arm Description
One anti-pseudomonal-β-lactam-based antibiotic (either meropenem or piperacillin-tazobactam)
Intervention Type
Drug
Intervention Name(s)
Murepavadin
Intervention Description
Murepavadin + ertapenem
Intervention Type
Drug
Intervention Name(s)
One anti-pseudomonal antibiotic
Intervention Description
Either meropenem or piperacillin-tazobactam
Primary Outcome Measure Information:
Title
All cause mortality rates
Time Frame
28 days after start of study treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Subject has received mechanical ventilation for at least 48h at the time of the randomisation OR at least 2 of the following signs or symptoms presenting within 24 hours prior to randomization: New onset of cough or worsening of baseline cough and/or dyspnea, tachypnea and/or hypoxemia and/or new onset of sputum or suctioned respiratory secretion characterized by purulent appearance indicative of bacterial infection or a worsening in character of purulent appearance Acute Physiology and Chronic Health Evaluation (APACHE) of 8 to 25, inclusive, within 24h prior to randomization Presence of new or progressive infiltrate on chest X-ray Presence of clinical criteria consistent with Pneumonia Strong clinical suspicion of pneumonia due to P. aeruginosa Key Exclusion Criteria: Known or suspected community-acquired bacterial pneumonia or viral, fungal, or parasitic pneumonia known hypersensitivity to any component of ertapenem, meropenem or to other drugs in the same class or demonstrated anaphylactic reactions to beta-lactams or a history of allergic reactions to any of the penicillins, cephalosporins, or β-lactamase inhibitors Severe liver or renal impairment Expected survival < 72 hours Evidence from an available surveillance culture of co infection with ertapenem , meropenem or piperacillin tazobactam resistant Gram negative pathogen(s) Women who are pregnant or nursing
Facility Information:
Facility Name
Research site
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
Facility Name
Research Site
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
Research site
City
Břeclav
Country
Czechia
Facility Name
Research site
City
Kolín
Country
Czechia
Facility Name
Research site
City
Argenteuil
Country
France
Facility Name
Research site
City
Hadera
Country
Israel
Facility Name
Research site
City
Tel Aviv
Country
Israel

12. IPD Sharing Statement

Learn more about this trial

Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas

We'll reach out to this number within 24 hrs